EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection

Margalida Mateu-Borrás iD, Spencer R Dublin iD, Jason Kang iD, Hunter L Monroe, Emel Sen-Kilic, Sarah J Miller, William T Witt, Joshua A Chapman, Gage M Pyles, Shreeram C Nallar, Annalisa B Huckaby, Evita Yang und 10 weitere

Infection and Immunity · 2025

DOI: 10.1128/iai.00330-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection and Immunity, 2025. Verfasst von Margalida Mateu-Borrás und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Antibodies, Monoclonal, Antibodies, Bacterial. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DOD | Defense Threat Reduction Agency (DTRA), Vaccine Development Center, West Virginia University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of infections attributed to antimicrobial-resistant (AMR) pathogens has increased exponentially over the recent decades reaching 1.27 million deaths worldwide in 2019. Without intervention, these infections are predicted to cause up to 10 million deaths a year and incur costs of up to 100 trillion US dollars globally by 2050. The emergence of AMR bacteria such as the ESKAPEE pathogens, and in particular Pseudomonas aeruginosa and species from the genus Burkholderia , underscores an urgent need for new therapeutic strategies. Monoclonal antibody (mAb) therapy offers a promising alternative to treat and prevent bacterial infections. In this study, we used peptides from highly conserved areas of the bacterial flagellin to generate monoclonal antibodies capable of broad binding to flagellated Gram-negative bacteria. We generated a broadly reactive IgG2bĸ mAb (WVDC-2109) that recognizes P. aeruginosa, Burkholderia sp., and other Gram-negative pathogens of interest. Characterization of the therapeutic potential of this antibody was determined using P. aeruginosa as model. In vitro characterization of WVDC-2109 demonstrated complement-mediated bactericidal activity and enhanced opsonophagocytosis of P. aeruginosa . Prophylactic administration of WVDC-2109 markedly improved survival and outcome in a lethal sepsis model and a sub-lethal murine pneumonia model of P. aeruginosa infection, reducing bacterial burden and inflammation. These findings suggest that WVDC-2109 and similar FliC-targeting antibodies could be valuable in preventing or treating diseases caused by P. aeruginosa as well as other life-threatening diseases of concern. IMPORTANCE Antimicrobial resistance (AMR) costs hundreds of thousands of lives and billions of dollars annually. To protect the population against these infections, it is imperative to develop new medical countermeasures targeting AMR pathogens like P. aeruginosa and Burkholderia sp. The administration of broadly reactive monoclonal antibodies can represent an alternative to treat and prevent infections caused by multi-drug-resistant bacteria. Unlike vaccines, antibodies can provide protection regardless of the immune status of the infected host. In this study, we generated an antibody capable of recognizing flagellin from P. aeruginosa and B. pseudomallei along with other Gram-negative pathogens of concern. Our findings demonstrate that the administration of the monoclonal antibody WVDC-2109 enhances survival rates and outcomes in different murine models of P. aeruginosa infection. These results carry significant implications in the field given that there are no available vaccines for P. aeruginosa .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsAntibodies, MonoclonalAntibodies, BacterialAnimalsMiceDisease Models, AnimalFemaleFlagellinHumansPhagocytosisMice, Inbred BALB C

Stichwörter der Autor:innen

BurkholderiaPseudomonas aeruginosaanti-microbial resistancemonoclonal antibodies

Substanzen

Antibodies, MonoclonalAntibodies, BacterialFlagellin

Autor:innen und Institutionen

  • Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA.
  • Vaccine Development Center, West Virginia University, Morgantown, West Virginia, USA.
  • Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University, Morgantown, West Virginia, USA.
  • School of Medicine, Division of Vaccine Research, Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, USA.
  • Lincoln Laboratory, MIT, Lexington, Massachusetts, USA.

ORCID-Profile: Margalida Mateu-Borrás, Spencer R Dublin, Jason Kang, Slawomir Lukomski, F Heath Damron, Mariette Barbier

Förderung

  • DOD | Defense Threat Reduction Agency (DTRA)
  • Vaccine Development Center, West Virginia University

Zitieren

APA

Mateu-Borrás, M., Dublin, S. R., Kang, J., Monroe, H. L., Sen-Kilic, E., Miller, S. J., Witt, W. T., Chapman, J. A., Pyles, G. M., Nallar, S. C., Huckaby, A. B., Yang, E., Rocuskie-Marker, C., Grund, M. E., Amin, M. S., Lukomski, S., Snyder, G. A., Ray, K., Lewis, G. K., …, & Barbier, M. (2025). Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection. Infection and Immunity. https://doi.org/10.1128/iai.00330-24

Vancouver

Mateu-Borrás M, Dublin SR, Kang J, Monroe HL, Sen-Kilic E, Miller SJ, et al. Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection. Infection and Immunity. 2025. doi:10.1128/iai.00330-24

BibTeX
@article{MateuBorrs2025,
  author = {Mateu-Borrás, Margalida and Dublin, Spencer R and Kang, Jason and Monroe, Hunter L and Sen-Kilic, Emel and Miller, Sarah J and Witt, William T and Chapman, Joshua A and Pyles, Gage M and Nallar, Shreeram C and Huckaby, Annalisa B and Yang, Evita and Rocuskie-Marker, Carleena and Grund, Megan E and Amin, Md Shahrier and Lukomski, Slawomir and Snyder, Greg A and Ray, Krishanu and Lewis, George K and Ricke, Darrell O and Damron, F Heath and Barbier, Mariette},
  title = {Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection},
  journal = {Infection and Immunity},
  year = {2025},
  doi = {10.1128/iai.00330-24}
}
Kostenlos starten →